Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: ADHD - Combined Type

In brief

The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.

Key facts

Study ID

NCT04781972

Run by

Johns Hopkins University

People needed

30

Starts

2021-07-27

Expected to finish

2029-04-30

Last updated by the study team

2025-10-16

Who can join

Age: 6 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• right handed

You may not qualify if…

• pregnant or breast feeding
• past or current neurological disorder
• non-ADHD cause of cognitive impairment
• uncontrolled medical disorder
• head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
• having an adverse reaction to methylphenidate, or other stimulant medication
• having a contraindication to MRI
• current smoking

Where it is running

• Johns Hopkins School of Medicine — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.